New Platform for Fast and Efficient Antibody Discovery Launched

Enpicom BV announces a major release of its ImmunoGenomiX (IGX) Platform featuring the new Antibody Discovery Module (ADM). This solution will allow scientists in biopharmaceutical companies and academia, as well as service providers working in the antibody discovery field, to make the most of their Sanger and NGS data and independently perform complex analyses.

The two new Apps developed for the ADM release are IGX-Cluster and IGX-Branch. IGX-Cluster groups sequences based on user-defined parameters such as CDR3 similarity, gene usage, and CDR3 length. It effortlessly performs large clustering tasks in the cloud and supports a wide variety of workflows for both paired and unpaired receptor chains. Subsequently, IGX-Branch creates interactive visualisations to prioritise clusters and pick antibody candidates for follow-up analysis through information-rich phylogenetic trees.

Enpicom’s IGX Platform is a professional tool to manage, analyse, integrate, and visualise immune repertoire sequencing data in a single environment. Technology-agnostic and code-free, it enables scientists to securely and effortlessly analyse immune repertoires. Together with the two new Apps introduced today, it provides an ideal setup for crucial tasks like candidate selection and hit expansion, thus creating a versatile system to discover promising antibody candidates. 

Other prominent new features released today include revamped receptor profiling workflows and vastly improved metadata importing. The earlier announced collaboration with MiLaboratories has resulted in a new MiXCR App, fully embedded in the platform.